Sara Hurvitz, MD
Hematology & Oncology · Seattle, WANPI 1972527810
Payments from drug & device makers
Across 930 payments — averaging $11,702 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$4.7M
- Seagen Inc.$2.2M
- Novartis$1.3M
- Sanofi US Services Inc.$619K
- Hoffmann-la Roche Limited$529K
- G1 Therapeutics, Inc.$361K
- plus $1.2M from 19 others
Across 81 payments — averaging $1239.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$31K
- Pfizer$31K
- F. Hoffmann-la Roche AG$30K
- Amgen$6K
- Sanofi$2K
- Eli Lilly$323
- plus $107 from 1 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 296 | $4,677,145 |
| Seagen Inc. | 264 | $2,198,718 |
| Novartis | 33 | $1,261,654 |
| Sanofi US Services Inc. | 25 | $618,765 |
| Hoffmann-la Roche Limited | 42 | $529,142 |
| G1 Therapeutics, Inc. | 82 | $360,893 |
| Pfizer | 45 | $259,362 |
| Eli Lilly | 36 | $246,340 |
| Puma Biotechnology, Inc. | 10 | $230,374 |
| Radius Health, Inc. | 9 | $131,856 |
| Macrogenics, Inc. | 17 | $102,279 |
| Stemline Therapeutics Inc. | 12 | $92,880 |
| Pharmacosmos Therapeutics Inc. | 24 | $66,803 |
| Janssen Research & Development, LLC | 1 | $39,961 |
| Genentech, Inc. | 3 | $36,340 |
| Immunomedics, Inc. | 1 | $10,704 |
| F. Hoffmann-la Roche AG | 13 | $10,626 |
| Gilead | 6 | $4,576 |
| Jazz Pharmaceuticals Inc. | 2 | $2,370 |
| Boehringer Ingelheim International GmbH | 1 | $682 |
| Sanofi | 1 | $500 |
| Bayer | 1 | $350 |
| Roche Products Limited | 4 | $210 |
| Astrazeneca UK Limited | 1 | $117 |
| AstraZeneca | 1 | $25 |
How this compares
$10,882,671 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Seattle
- Mazyar ShadmanSeattle$36.8M
- Ryan CassadaySeattle$22.7M
- John PesandoSeattle$15.7M
- Andrew CowanSeattle$15M
- Stephen SmithSeattle$12.6M
- Stephanie LeeSeattle$11.2M
- Chaitra UjjaniSeattle$10.6M
- Lawrence FongSeattle$9.7M
- Cameron TurtleSeattle$8.2M
- Ryan LynchSeattle$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.